Antibodies have emerged as crucial therapeutics in cancer treatment, with multiple clinically relevant mechanisms of action. They can manipulate tumor-related signaling and exhibit immunomodulatory properties, promoting anti-tumor immune responses. The article highlights the structural and functional features of antibodies, including their ability to activate or inhibit immune system molecules. Antibodies targeting tumor antigens, such as growth factor receptors (EGFR, HER2), and those targeting the tumor microenvironment, such as angiogenesis inhibitors (VEGF), have shown therapeutic efficacy. The article also discusses the importance of FcγRs in mediating antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), and the role of cross-presentation in inducing adaptive immune responses. Additionally, it explores combination therapies, including combinations with chemotherapy, radiation, targeted therapy agents, and vaccines, which enhance the anti-tumor efficacy of antibodies. The future prospects of antibody-based therapies are promising, with ongoing research focusing on identifying new targets, optimizing antibody structures, and combining antibodies with other immunomodulatory approaches.Antibodies have emerged as crucial therapeutics in cancer treatment, with multiple clinically relevant mechanisms of action. They can manipulate tumor-related signaling and exhibit immunomodulatory properties, promoting anti-tumor immune responses. The article highlights the structural and functional features of antibodies, including their ability to activate or inhibit immune system molecules. Antibodies targeting tumor antigens, such as growth factor receptors (EGFR, HER2), and those targeting the tumor microenvironment, such as angiogenesis inhibitors (VEGF), have shown therapeutic efficacy. The article also discusses the importance of FcγRs in mediating antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), and the role of cross-presentation in inducing adaptive immune responses. Additionally, it explores combination therapies, including combinations with chemotherapy, radiation, targeted therapy agents, and vaccines, which enhance the anti-tumor efficacy of antibodies. The future prospects of antibody-based therapies are promising, with ongoing research focusing on identifying new targets, optimizing antibody structures, and combining antibodies with other immunomodulatory approaches.